8-KCorporate ChangesExhibits & Filings

AMGEN INC 8-K Report, Bylaw Amendment (Feb 17, 2016)

Filed February 17, 2016For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on February 16, 2016, reporting an amendment to its corporate governance. Specifically, on February 15, 2016, the Board of Directors adopted Amended and Restated Bylaws. The primary driver for this amendment was to implement proxy access, allowing eligible long-term stockholders to nominate directors for inclusion in the company's proxy materials. This change empowers significant shareholders who meet specific ownership thresholds (3% or more of common stock for at least three years) to nominate a limited number of directors (up to 20% of the Board or two nominees). This move reflects a broader trend in corporate governance and provides shareholders with a greater voice in board composition, which could be viewed positively by investors seeking greater accountability from management.

Key Highlights

  • 1Amgen adopted Amended and Restated Bylaws effective February 15, 2016.
  • 2The primary purpose of the amendment is to implement 'proxy access'.
  • 3Proxy access allows eligible stockholders to nominate director candidates for inclusion in the company's proxy statement.
  • 4Eligible stockholders must own at least 3% of Amgen's outstanding common stock continuously for at least three years.
  • 5The bylaws permit the nomination of up to the greater of 20% of the Board or two director nominees.
  • 6Specific requirements for both the nominating stockholders and the director nominees are detailed within the Bylaws.
  • 7This amendment aims to enhance shareholder engagement in board-level decisions.

Frequently Asked Questions

Proxy access is a corporate governance mechanism that allows eligible shareholders to nominate directors for election at the company's annual meeting and have those nominees included in the company's proxy materials. Amgen implemented it to give significant, long-term shareholders a greater ability to influence board composition and enhance corporate governance.

To be eligible to use Amgen's proxy access provisions, a shareholder or a group of shareholders must collectively own at least 3% of the company's outstanding common stock continuously for at least three years prior to the date of nomination.

Under Amgen's new bylaws, eligible shareholders can nominate director candidates representing up to the greater of 20% of the Board of Directors or two nominees.

This change primarily affects the nomination process for directors. It allows eligible shareholders to nominate candidates to appear on the company's proxy card. As an individual investor, you will still vote your shares for or against all director nominees, whether nominated by the company's board or by eligible shareholders through proxy access.